OKYO Pharma LTD: OKYO Pharma Limited (OKYO or the Company) - OKYO publicly files a registration statement with the SEC

LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease

Related Keywords

New York ,United States ,United Kingdom ,London ,City Of ,Irina Koffler ,Ramnarain Jaigobind ,Gabriele Cerrone ,Priyanka Mahajan ,Garys Jacob ,Main Market Of London Stock Exchange ,Pharma Limited ,Financial Services ,Nasdaq ,Exchange Commission ,European Union Withdrawal ,List Of The Financial Conduct Authority ,American Depositary Shares ,Official List ,Financial Conduct Authority ,London Stock Exchange ,European Economic Area ,European Union ,Kingdom Prospectus ,Ordinary Shares ,Standard Listing ,Main Market ,United Kingdom Prospectus Regulation ,Kingdom Admission ,United Kingdom Admission Prospectus ,Chief Executive ,Investor Relations ,United Kingdom Prospectus ,Markets Act ,Financial Promotion ,Tokyo ,Dharma ,Imited ,Company ,Publicly ,Files ,Registration ,Statement ,